Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 222

1.

Response to comment on cefalu et Al. The alarming and rising costs of diabetes and prediabetes: a call for action! Diabetes care 2014;37:3137-3138.

Cefalu WT, Petersen MP, Ratner RE.

Diabetes Care. 2015 May;38(5):e82-3. doi: 10.2337/dc15-0215. No abstract available.

PMID:
25908165
2.
3.

Dietary chromium supplementation for targeted treatment of diabetes patients with comorbid depression and binge eating.

Brownley KA, Boettiger CA, Young L, Cefalu WT.

Med Hypotheses. 2015 Mar 27. pii: S0306-9877(15)00135-8. doi: 10.1016/j.mehy.2015.03.020. [Epub ahead of print]

PMID:
25838140
4.

Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes.

Cefalu WT, Stenlöf K, Leiter LA, Wilding JP, Blonde L, Polidori D, Xie J, Sullivan D, Usiskin K, Canovatchel W, Meininger G.

Diabetologia. 2015 Mar 27. [Epub ahead of print]

PMID:
25813214
5.

Health policy and diabetes care: is it time to put politics aside?

Herman WH, Cefalu WT.

Diabetes Care. 2015 May;38(5):743-5. doi: 10.2337/dc15-0348. Epub 2015 Mar 22. No abstract available.

PMID:
25802325
6.

Modulation of sphingolipid metabolism with calorie restriction enhances insulin action in skeletal muscle.

Obanda DN, Yu Y, Wang ZQ, Cefalu WT.

J Nutr Biochem. 2015 Mar 5. pii: S0955-2863(15)00040-6. doi: 10.1016/j.jnutbio.2015.01.007. [Epub ahead of print]

PMID:
25771159
7.

SGLT2 inhibitors: the latest "new kids on the block"!

Cefalu WT, Riddle MC.

Diabetes Care. 2015 Mar;38(3):352-4. doi: 10.2337/dc14-3048. No abstract available.

PMID:
25715412
8.

The “evidence” is in! It does get better!

Cefalu WT.

Diabetes Care. 2015 Jan;38(1):3-5. No abstract available.

PMID:
25688407
9.

Innovative approaches to understanding and addressing health disparities in diabetes care and research.

Cefalu WT, Golden SH.

Diabetes Care. 2015 Feb;38(2):186-8. doi: 10.2337/dc14-2748. No abstract available.

PMID:
25614688
10.

In vivo effects of dietary quercetin and quercetin-rich red onion extract on skeletal muscle mitochondria, metabolism, and insulin sensitivity.

Henagan TM, Cefalu WT, Ribnicky DM, Noland RC, Dunville K, Campbell WW, Stewart LK, Forney LA, Gettys TW, Chang JS, Morrison CD.

Genes Nutr. 2015 Jan;10(1):451. doi: 10.1007/s12263-014-0451-1. Epub 2014 Dec 27.

11.

The alarming and rising costs of diabetes and prediabetes: a call for action!

Cefalu WT, Petersen MP, Ratner RE.

Diabetes Care. 2014 Dec;37(12):3137-8. doi: 10.2337/dc14-2329. No abstract available.

PMID:
25414386
12.

Statement of principle.

Cefalu WT, Nair KS, Seaquist ER, Zierath J, Boulton AJ, LeRoith D, Harrell RM, Grunberger G, Wartofsky L, Gore AC, Wierman ME, Hammes SR, Lange CA, Santen RJ.

Horm Cancer. 2015 Feb;6(1):1. doi: 10.1007/s12672-014-0206-x. No abstract available.

PMID:
25410830
13.

Body mass index and the risk of all-cause mortality among patients with type 2 diabetes mellitus.

Zhao W, Katzmarzyk PT, Horswell R, Wang Y, Li W, Johnson J, Heymsfield SB, Cefalu WT, Ryan DH, Hu G.

Circulation. 2014 Dec 9;130(24):2143-51. doi: 10.1161/CIRCULATIONAHA.114.009098. Epub 2014 Nov 5.

PMID:
25378546
14.

Statement of principle.

Cefalu WT, Nair KS, Seaquist ER, Zierath J, Boulton AJ, LeRoith D, Harrell RM, Grunberger G, Wartofsky L, Gore AC, Wierman ME, Hammes SR, Lange CA, Santen RJ.

Endocr Rev. 2014 Dec;35(6):850. doi: 10.1210/er.2014-1089. Epub 2014 Nov 3. No abstract available.

PMID:
25365740
15.

Statement of principle.

Cefalu WT, Nair KS, Seaquist ER, Zierath J, Boulton AJ, LeRoith D, Harrell RM, Grunberger G, Wartofsky L, Gore AC, Wierman ME, Hammes SR, Lange CA, Santen RJ.

J Clin Endocrinol Metab. 2014 Dec;99(12):4376. doi: 10.1210/jc.2014-3958. No abstract available.

PMID:
25365410
16.

Response to comment on Home et al. Insulin therapy in people with type 2 diabetes: opportunities and challenges? Diabetes care 2014;37:1499-1508.

Home P, Riddle M, Cefalu WT, Bailey CJ, Bretzel RG, Del Prato S, Leroith D, Schernthaner G, van Gaal L, Raz I.

Diabetes Care. 2014 Nov;37(11):e247. doi: 10.2337/dc14-1790. No abstract available.

PMID:
25342843
17.

Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy.

Rosenstock J, Cefalu WT, Lapuerta P, Zambrowicz B, Ogbaa I, Banks P, Sands A.

Diabetes Care. 2015 Mar;38(3):431-8. doi: 10.2337/dc14-0890. Epub 2014 Sep 11.

PMID:
25216510
18.

Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum.

Cefalu WT, Buse JB, Del Prato S, Home PD, LeRoith D, Nauck MA, Raz I, Rosenstock J, Riddle MC.

Diabetes Care. 2014 Sep;37(9):2647-59. doi: 10.2337/dc14-1395.

PMID:
25147257
19.

Status of Diabetes Care: "It just doesn't get any better . . . or does it?".

Cefalu WT, Boulton AJ, Tamborlane WV, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Weinger K, Blonde L, de Groot M, Riddle MC, Henry RR, Hill Golden S, Rich S, Reynolds L.

Diabetes Care. 2014 Jul;37(7):1782-5. No abstract available.

PMID:
25093231
20.

Blood pressure and heart failure risk among diabetic patients.

Zhao W, Katzmarzyk PT, Horswell R, Li W, Wang Y, Johnson J, Heymsfield SB, Cefalu WT, Ryan DH, Hu G.

Int J Cardiol. 2014 Sep;176(1):125-32. doi: 10.1016/j.ijcard.2014.06.051. Epub 2014 Jul 6.

PMID:
25037690
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk